Viruses, not bacteria, are the most commonly detected pathogen in US adults hospitalized with pneumonia; however, neither viruses nor bacteria were detected in the majority of these patients despite current diagnostic tests.
Viruses, not bacteria, are the most commonly detected pathogen in US adults hospitalized with pneumonia; however, neither viruses nor bacteria are detected in the majority of these patients despite current diagnostic tests, according to study conducted by the CDC.
The researchers enrolled 2488 adults hospitalized with community-acquired pneumonia at hospitals in Chicago and Nashville and discovered a need for more sensitive rapid diagnostic tests to identify pneumonia.
During the 2-and-a-half year study, known as the CDC Etiology of Pneumonia in the Community (EPIC) study, neither viruses nor bacteria were detected in 62% of participants. The results of the study were published in the New England Journal of Medicine.
“Pneumonia is a leading cause of hospitalization and death among adults in the United States and in 2011 the medical costs exceeded $10 billion,” CDC Director Tom Frieden, MD, MPH, said in a statement. “Most of the time doctors are unable to pinpoint a specific cause of pneumonia. We urgently need more sensitive, rapid tests to identify causes of pneumonia and to promote better treatment.”
Viruses were detected in 27% of patients and bacteria in 14% of patients, according to the study. Among pneumonia patients, the human rhinovirus was the most commonly detected virus, followed by influenza.
According to Seema Jain, MD, lead author of the paper and medical epidemiologist in CDC’s Influenza Division, the frequency with which respiratory viruses were detected in hospitalized patients with pneumonia was higher than previously documented, which may be a result of improved diagnostics.
“However, what’s most remarkable is that despite how hard we looked for pathogens, no discernible pathogen was detected in 62% of adults hospitalized with pneumonia in the EPIC study,” Dr Jain said. “This illustrates the need for more sensitive diagnostic methods that can both help guide treatment at the individual level as well as inform public health policy for adult pneumonia at a population level.”
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
ICS Use Tied to Fewer Exacerbations in Patients With Bronchiectasis and Elevated Blood Eosinophils
June 6th 2025Inhaled corticosteroid (ICS) use was common among patients with bronchiectasis and was associated with reduced exacerbations and hospitalizations in those with elevated blood eosinophil counts.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More